Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
ConditionHidradenitis Suppurativa (HS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking Union Medical College
About this trial
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age ≥18 years
diagnosis of moderate-to-severe HS with Hurley stage II or III
Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors
Disqualifiers
active infections (e.g., viral hepatitis, active tuberculosis)
use of other biologics or systemic immunosuppressants within the past three months
severe organ dysfunction (e.g., hepatic or renal failure)
any other conditions that might affect study results
Trial population
All participants were treated at the Department of Dermatology, Peking Union Medical College Hospital
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Secukinumab
Drugsecukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels
Time frame
From enrollment to the end of treatment at Week 12Secondary outcomes
1
Dermatology Life Quality Index
Time frame
From enrollment to the end of treatment at week 12Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov